Printed: Feb. 12, 2024 at 7:12 a.m. ET
By Chris Wack
Gritstone Bio is pushing again the launch of its Section 2b head-to-head trial of its next-generation Covid-19 vaccine to the autumn of 2024 reasonably than the primary quarter of 2024.
The biotechnology firm stated the transfer is to permit use of totally GMP-grade uncooked supplies within the vaccine, which is predicted to extend the regulatory utility…
By Chris Wack
Gritstone Bio is pushing again the launch of its Section 2b head-to-head trial of its next-generation Covid-19 vaccine to the autumn of 2024 reasonably than the primary quarter of 2024.
The biotechnology firm stated the transfer is to permit use of totally GMP-grade uncooked supplies within the vaccine, which is predicted to extend the regulatory utility of the trial.
Gritstone stated it determined to make the transfer after latest communication with the U.S. Meals and Drug Administration and the Biomedical Superior Analysis and Improvement Authority.
This challenge has been supported in complete or partly with federal funds from the U.S. Division of Well being and Human Providers; Administration for Strategic Preparedness and Response; Biomedical Superior Analysis and Improvement Authority.
Write to Chris Wack at chris.wack@wsj.com
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.